Phase 4 Alzheimer's Disease Trial, Not Yet Recruiting NCT07579689 Sponsor: Hanyang University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 4 Alzheimer's Disease Trial, Not Yet Recruiting

NCT07579689
Not Yet Recruiting Phase 4

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People aged 20 years or older.
  • People with a Clinical Dementia Rating (CDR) score of 0.5 — this is a scale used to measure mild memory and thinking changes, and a score of 0.5 indicates very mild impairment (confirm with trial site).
  • People for whom a doctor has determined that treatment with Ginkgo biloba extract is clinically appropriate.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People currently taking medications known as cholinesterase inhibitors, such as donepezil, rivastigmine, or galantamine.
  • People who decline to give their formal agreement to take part in the trial.
  • People who have a neurological or psychiatric condition other than Alzheimer's disease that could affect memory or thinking.
  • People with a known allergy or sensitivity to Ginkgo biloba extract or any of its ingredients.
  • People who are pregnant.
  • People with certain genetic conditions related to difficulty processing lactose or related sugars, including galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
  • People who have a bleeding disorder, or who need to take certain ongoing medications that may interfere with the study drug — such as blood thinners, anticlotting medications, clot-dissolving medications, or certain blood flow medications.
  • People whom the trial investigators or staff consider unsuitable for the study for any other reason, or who may not be able to follow the study procedures.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: +82-31-560-2264

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Hanyang University
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 December 2028

Primary endpoints

Change from Baseline in Plasma p-tau217 at 6 Months

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov